M&A Deal Summary

OSI Pharmaceuticals Acquires Eyetech Pharmaceuticals

On August 22, 2005, OSI Pharmaceuticals acquired life science company Eyetech Pharmaceuticals from Alta Partners for 935M USD

Acquisition Highlights
  • This is OSI Pharmaceuticals’ 3rd transaction in the Life Science sector.
  • This is OSI Pharmaceuticals’ largest (disclosed) transaction.
  • This is OSI Pharmaceuticals’ 3rd transaction in the United States.
  • This is OSI Pharmaceuticals’ 1st transaction in New Jersey.
Investment Fate
  • Eyetech Pharmaceuticals was divested to a consortium of strategic buyers in 2012 for 22M USD.

M&A Deal Summary
Date 2005-08-22
Target Eyetech Pharmaceuticals
Sector Life Science
Buyer(s) OSI Pharmaceuticals
Sellers(s) Alta Partners
Deal Type Add-on Acquisition
Deal Value 935M USD

Target

Eyetech Pharmaceuticals

Cedar Knolls, New Jersey, United States
Eyetech Pharmaceuticals was founded to discover and develop new drugs to reduce and prevent serious vision loss caused by eye disease. Eyetech's lead product, EYE001, addresses the two leading causes of blindness in the adult population-age-related macular degeneration (AMD) and diabetic macular edema (DME).

Search 201,839 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

OSI Pharmaceuticals

Farmingdale, New York, United States
Category Company
Founded 1983
Sector Life Science
DESCRIPTION

OSI Pharmaceuticals Inc. is an oncology drug discovery and translational research company, primarily focused on the discovery of molecular targeted therapies.

DEAL STATS #
Overall 3 of 3
Sector (Life Science) 3 of 3
Type (Add-on Acquisition) 2 of 2
State (New Jersey) 1 of 1
Country (United States) 3 of 3
Year (2005) 1 of 1
Size (of disclosed) 1 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2003-02-11 Cell Pathways

Horsham, Pennsylvania, United States

Cell Pathways, Inc develops and commercializes drugs for the prevention and treatment of cancer.

Buy $32M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2012-03-01 Eyetech Pharmaceuticals

Cedar Knolls, New Jersey, United States

Eyetech Pharmaceuticals was founded to discover and develop new drugs to reduce and prevent serious vision loss caused by eye disease. Eyetech's lead product, EYE001, addresses the two leading causes of blindness in the adult population-age-related macular degeneration (AMD) and diabetic macular edema (DME).

Sell $22M

Seller(S) 1

SELLER

Alta Partners

Jackson, Wyoming, United States

Investor Investor Investor Investor

Category Venture Capital Firm
Founded 1996
PE ASSETS 2.6B USD
Size Large
Type Sector Focused
DESCRIPTION

Alta Partners is a venture capital firm that targets investments in early and later stage life science companies, including biopharmaceuticals, medical technology, and information technology businesses. Alta was formed as an early stage investor but has since expanded its investment range to provide later stage growth capital to private and young public companies. Alta was established in 1996 and is headquartered in San Francisco, California.

DEAL STATS #
Overall 24 of 84
Sector (Life Science) 15 of 64
Type (Add-on Acquisition) 16 of 45
State (New Jersey) 2 of 3
Country (United States) 22 of 74
Year (2005) 5 of 6
Size (of disclosed) 4 of 23
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2005-08-22 ABIONYX Pharma

Balma, France

ABIONYX Pharma is an international biopharmaceutical company dedicated to the discovery and development of innovative HDL therapies for the treatment of cardiovascular and metabolic diseases. ABIONYX Pharma was founded in 2005 and is based in Labege, France.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2005-08-23 Alba Therapeutics

Baltimore, Maryland, United States

Alba Therapeutics is focused on the development of novel therapeutics for the treatment of inflammatory and immune-mediated diseases caused by the malfunction of tight junctions in the body. Initial target diseases are Celiac Disease and Type I Diabetes. The Company is in Phase II studies.

Buy -
Mergr

Product

Company

Legal